serine peptidase inhibitor, Kunitz type 2Genealiases: DIAR3 · HAI-2 · HAI2 · Kop · PB
Q-omics provides the consensus-scored SPINT2 profile across patient tissues and cancer cell-line models. SPINT2 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SPINT2 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, SPINT2 RNA expression shows 17,779 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, HNSC, and THYM as cancer lineages where SPINT2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SPINT2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SPINT2 survival associations across molecular data types. SPINT2 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SPINT2 RNA expression–survival associations across cancer types. High SPINT2 expression shows unfavorable associations in CESC, LUAD and LAML, but favorable associations in KIRC, SKCM and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify KIRC as the clearest survival context for SPINT2 RNA expression.
This table summarizes SPINT2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 7. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for SPINT2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SPINT2 shows lower tumor expression in KICH and higher tumor expression in HNSC, LUAD, STAD, BLCA and LUSC. The HNSC box plot shows higher SPINT2 RNA expression in tumor versus normal tissue (log2 FC = +0.772, t-test p < 0.001).
This table shows molecular features associated with SPINT2 in patient tissues and cancer cell lines. In patient samples, SPINT2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, SPINT2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
